Trending News Today: Epidiolex Meets Primary Goal in Trial for Tuberous Sclerosis Complex

Top news of the day from across the health care landscape.

GW Pharmaceuticals’ cannabidiol drug Epidiolex met the primary goal of treating seizures in patients with tuberous sclerosis complex (TSC) during a late-stage trial, Reuters reported. According to the article, the trial tested 2 doses of the drug versus a placebo in treatment-resistant TSC patients between 1 and 65 years old. The data showed that the doses reduced seizures by 47.5% and 48.6%, respectively, compared with a 26.5% reduction in patients taking a placebo, the article reported.

Some ingredients found in sunscreen may be absorbed into the bloodstream after just 1 day of use, according to an FDA study published in the Journal of the American Medical Association. According to the study, FDA researchers found users of products with the active ingredient avobenzone, oxybenzone, otocrylene, or ecamsule absorb higher levels than current US guidelines allow. In some instances, the data showed that the levels observed were up to 40 times higher than that threshold, indicating a need for further study by manufacturers, the study noted.

In an effort to reduce the spread of vaccine misinformation, Instagram said it is developing a “pop-up” that would appear on inaccurate vaccine-related content, The Hill reported. According to the article, an Instagram spokesperson said the company has been working on a message that would appear when users search for vaccine misinformation. Facebook, which owns Instagram, also recently announced a plan to reduce the circulation of anti-vaccine content on its platforms, the article reported.